Literature DB >> 30963179

Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.

Mackenzie L Cottrell1, Heather M A Prince2, Amanda P Schauer1, Craig Sykes1, Kaitlyn Maffuid1, Amanda Poliseno1, Tae-Wook Chun3, Erin Huiting3, Frank Z Stanczyk4, Anne F Peery5, Evan S Dellon5, Jessica L Adams6,7, Cindy Gay2, Angela D M Kashuba1,2.   

Abstract

Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; feminizing hormone therapy; lower gastrointestinal tract; preexposure prophylaxis; transgender

Mesh：

Substances：

Year:  2019        PMID： 30963179      PMCID： PMC7188232          DOI： 10.1093/cid/ciz290

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

Review 1.  The 5'-nucleotidases as regulators of nucleotide and drug metabolism.

Authors:  Sally Anne Hunsucker; Beverly S Mitchell; Jozef Spychala
Journal:  Pharmacol Ther       Date:  2005-07       Impact factor: 12.310

2.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

3.  Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

Authors:  J Gerardo García-Lerma; Wutyi Aung; Mian-er Cong; Qi Zheng; Ae S Youngpairoj; James Mitchell; Angela Holder; Amy Martin; Susan Kuklenyik; Wei Luo; Carol Yen-Chin Lin; Debra L Hanson; Ellen Kersh; Chou-Pong Pau; Adrian S Ray; James F Rooney; William A Lee; Walid Heneine
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

4.  The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

Authors:  David M Margolis; Stephen Kewn; Jason J Coull; Loyda Ylisastigui; Diana Turner; Holly Wise; Mohammed M Hossain; E Randall Lanier; Leslie M Shaw; David Back
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

5.  Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.

Authors:  Benoît Lacombe; Marina Morel; Florence Margottin-Goguet; Bertha Cecilia Ramirez
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 6.  Regulation of mucosal immunity in the female reproductive tract: the role of sex hormones in immune protection against sexually transmitted pathogens.

Authors:  Charles R Wira; John V Fahey; Marta Rodriguez-Garcia; Zheng Shen; Mickey V Patel
Journal:  Am J Reprod Immunol       Date:  2014-04-16       Impact factor: 3.886

Review 7.  Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.

Authors:  Stefan D Baral; Tonia Poteat; Susanne Strömdahl; Andrea L Wirtz; Thomas E Guadamuz; Chris Beyrer
Journal:  Lancet Infect Dis       Date:  2012-12-21       Impact factor: 25.071

8.  Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.

Authors:  Biswajit Das; Curtis Dobrowolski; Benjamin Luttge; Saba Valadkhan; Nicolas Chomont; Rowena Johnston; Peter Bacchetti; Rebecca Hoh; Monica Gandhi; Steven G Deeks; Eileen Scully; Jonathan Karn
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

9.  Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.

Authors:  Zheng Shen; John V Fahey; Jack E Bodwell; Marta Rodriguez-Garcia; Richard M Rossoll; Sarah G Crist; Mickey V Patel; Charles R Wira
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Authors:  Madeline B Deutsch; David V Glidden; Jae Sevelius; Joanne Keatley; Vanessa McMahan; Juan Guanira; Esper G Kallas; Suwat Chariyalertsak; Robert M Grant
Journal:  Lancet HIV       Date:  2015-11-06       Impact factor: 12.767
View more
  18 in total

Review 1.  Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation.

Authors:  Victoria E Powell; Kevin M Gibas; Joshua DuBow; Douglas S Krakower
Journal:  Curr Infect Dis Rep       Date:  2019-06-21       Impact factor: 3.725

2.  Management and Prevention of HIV Among Transgender Adults.

Authors:  Asa E Radix
Journal:  Top Antivir Med       Date:  2020 Dec-Jan

3.  Screening and Enrollment by Sex in Human Immunodeficiency Virus Clinical Trials in the United States.

Authors:  Laura M Smeaton; Deborah Kacanek; Kateryna Mykhalchenko; Kristine Coughlin; Karin L Klingman; Susan L Koletar; Elizabeth Barr; Ann C Collier
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

Review 4.  Cardiovascular Disease Risk Among Transgender People with HIV.

Authors:  Madeline Cetlin; Evelynne S Fulda; Sarah M Chu; Ole-Petter R Hamnvik; Tonia Poteat; Markella V Zanni; Mabel Toribio
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-09       Impact factor: 5.071

5.  Factors Influencing Willingness to Use Human Immunodeficiency Virus Preexposure Prophylaxis Among Transgender Women in India.

Authors:  Venkatesan Chakrapani; Simran Shaikh; Visvanathan Arumugam; Umesh Chawla; Sonal Mehta
Journal:  Transgend Health       Date:  2021-04-16

6.  Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices.

Authors:  Sarah K Calabrese; Rachel W Galvao; John F Dovidio; Tiara C Willie; Cara B Safon; Clair Kaplan; Abigail Caldwell; Oni Blackstock; Nicole J Phillips; Trace S Kershaw
Journal:  AIDS Patient Care STDS       Date:  2020-03       Impact factor: 5.078

7.  TransPrEP: Results from the Pilot Study of a Social Network-Based Intervention to Support PrEP Adherence Among Transgender Women in Lima, Peru.

Authors:  Jesse Clark; Sari Reisner; Amaya Perez-Brumer; Leyla Huerta; Hugo Sanchez; Kathleen Moriarty; Maria Mamani Luque; Hideaki Okochi; Ximena Salazar; Matthew Mimiaga; Jorge Sanchez; Monica Gandhi; Kenneth H Mayer; Javier R Lama
Journal:  AIDS Behav       Date:  2021-01-01

Review 8.  Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.

Authors:  Melissa E Badowski; Nicholas Britt; Emily C Huesgen; Michelle M Lewis; Misty M Miller; Kathleen Nowak; Elizabeth Sherman; Renata O Smith
Journal:  Pharmacotherapy       Date:  2021-02-27       Impact factor: 4.705

9.  Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.

Authors:  Lauren R Cirrincione; Anthony T Podany; Joshua P Havens; Sara H Bares; Shetty Ravi Dyavar; Yeongjin Gwon; Tanner M Johnson; N Jean Amoura; Courtney V Fletcher; Kimberly K Scarsi
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

10.  Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation.

Authors:  Venkatesan Chakrapani; Murali Shunmugam; Shruta Rawat; Dicky Baruah; Ruban Nelson; Peter A Newman
Journal:  AIDS Patient Care STDS       Date:  2020-01-17       Impact factor: 5.078
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.